Tylovet® 40 Tylovet® 100 — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Tylovet® 40 Tylovet® 100

Active ingredient

Tylosin Phosphate

Application type

ANADA

Sponsor

Huvepharma EOOD

Applications on record

1

First published

June 23, 2021

Adverse event reports

Source: openFDA VeDDRA

229

Reports mentioning this ingredient

December 21, 2009 – March 16, 2026

88

Classified serious

per reporter assessment

46

Lack of expected efficacy

resistance signal

1

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “TYLOSIN PHOSPHATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Death	49
Lack of efficacy - NOS	19
Lack of efficacy (bacteria) - NOS	17
Pneumonia	15
Lameness	13
Bloated	12
Ruminal bloat	10
Peritonitis	10
Respiratory tract disorder NOS	10
NT - Abnormal necropsy finding NOS	9
Found dead	9
Unclassifiable adverse event	9
Death by euthanasia	8
Respiratory signs	6
Loose stool	6
Behavioural disorder NOS	6
Musculoskeletal disorder NOS	5
Liver disorder NOS	5
Not eating	5
Seal, Abnormal	5

Species affected

Source: openFDA VeDDRA

Cattle 147 Pig 32 Dog 17 Chicken 9 Human 4 Horse 1

Regulatory context

Abbreviated New Animal Drug Application (ANADA). A generic animal drug demonstrating bioequivalence, pharmaceutical equivalence and identical manufacturing criteria to the pioneer application. Veterinary generics have no formal therapeutic-equivalence coding system; they match the pioneer NADA specification instead.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient